ライフサイエンスコーパス: parenteral

1 tic therapy was 6 weeks, of which 1 week was parenteral.

2 ral drugs (ARVs) were recently developed for parenteral administration at monthly or longer intervals

3 more polar molecules that currently require parenteral administration because the vaginal epithelium

4 for patients, since repetitive and long-term parenteral administration is required as most proteins a

5 Neutralization of macaque IL-15 by parenteral administration of Hu714MuXHu reduces (>95%) c

6 Parenteral administration of IL-4 resulted in augmented

7 on absorption by activation of HIF-2alpha or parenteral administration of iron-dextran in HIF-2alpha

8 Here we show that long-term parenteral administration of superphysiological doses of

9 with the following different adjuvants after parenteral administration to mice: alum, a derivative of

10 rising fewer injections and oral rather than parenteral administration, compared with a reference tre

11 Furthermore, after parenteral administration, the FhHDM-1 peptide interacte

12 FpEF, but its use is limited by the need for parenteral administration.

13 f less than 100nm are excellently suited for parenteral administration.

14 ltiple sclerosis and rheumatoid arthritis by parenteral administration.

15 Compound 12, a promising parenteral agent for the treatment of MET-dependent canc

16 ulants; 4) evaluate whether to bridge with a parenteral agent periprocedurally; 5) offer advice on ho

17 ive phase, including a fluoroquinolone and a parenteral agent, would be associated with a reduced ris

18 Ceftaroline is the newest of the approved parenteral agents for SSSIs caused by MRSA.

19 s isolates resistant to fluoroquinolones and parenteral agents-we found that monthly exposure to an a

20 ental introduction of amino acids (Inc-AAs)] parenteral amino acid delivery within 24 h of birth on b

21 In patients with a stable parenteral amino acid supply (n = 7), the median net pro

22 Imm-RDI of parenteral amino acids does not benefit body composition

23 se of short-acting inhaled beta2-stimulants, parenteral aminophylline, and slow-release theophylline

24 randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, al

25 the human mineral and endocrine response to parenteral and duodenal acute phosphate loads.

26 Daily parenteral and enteral manganese intakes were calculated

27 ediatrics, the ASN, the American Society for Parenteral and Enteral Nutrition, the Academy of Nutriti

28 After controlling for GA, higher parenteral and total manganese intakes were associated w

29 This parenteral antibacterial agent has a dual mechanism of a

30 admission for patients prescribed outpatient parenteral antibiotic therapy (OPAT) at hospital dischar

31 Parenteral antibiotic therapy for young infants (aged 0-

32 Ceftriaxone is recommended when parenteral antibiotic therapy is recommended.

33 l infections, and duration of total (or just parenteral) antibiotic sue.

34 ws: 1) blood cultures before antibiotics; 2) parenteral antibiotics administered less than or equal t

35 Drug-induced eosinophilia is common with parenteral antibiotics.

36 and older and exposed to one or more oral or parenteral antibiotics.

37 efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy w

38 red with accelerated infusion alteplase plus parenteral anticoagulants (RR 1.47 [95% CI 1.10-1.98] fo

39 Parenteral anticoagulants administered in doses greater

40 with accelerated infusion of alteplase with parenteral anticoagulants as background therapy, strepto

41 alteplase, tenecteplase, and reteplase with parenteral anticoagulants as background therapy.

42 Hospital utilization rates of parenteral anticoagulants for AF during sepsis varied (m

43 tors; RR 1.88 [1.24-2.86] for reteplase plus parenteral anticoagulants plus glycoprotein inhibitors).

44 .47 [95% CI 1.10-1.98] for tenecteplase plus parenteral anticoagulants plus glycoprotein inhibitors;

45 .10-1.45] for non-accelerated alteplase plus parenteral anticoagulants).

46 A total of 13611 patients (35.3%) received parenteral anticoagulants, while 24971 (64.7%) did not.

47 14 [95% CI 1.05-1.24] for streptokinase plus parenteral anticoagulants; RR 1.26 [1.10-1.45] for non-a

48 urred more often among patients who received parenteral anticoagulation (1163 of 13505 [8.6%]) than p

49 05 [8.6%]) than patients who did not receive parenteral anticoagulation (979 of 13505 [7.2%]; RR, 1.2

50 ]) and did not (185 of 13505 [1.4%]) receive parenteral anticoagulation (relative risk [RR], 0.94; 95

51 Risk of ischemic stroke associated with parenteral anticoagulation did not differ significantly

52 ses, including hospital utilization rates of parenteral anticoagulation for AF as an instrument for a

53 Among patients with AF during sepsis, parenteral anticoagulation was not associated with reduc

54 med melioidosis who had received a course of parenteral antimicrobial drugs.

55 Outpatient parenteral antimicrobial therapy (OPAT) is accepted as s

56 Outpatient parenteral antimicrobial therapy (OPAT) is now standard

57 fazolin for MSSA infection in the outpatient parenteral antimicrobial therapy clinic at Massachusetts

58 Egypt are not well understood, but the mass parenteral antischistosomal therapy (PAT) campaigns in t

59 al MS medications need to be administered by parenteral application but are modestly effective.

60 Parenteral ARS is associated with a risk of delayed anem

61 both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen with the standard five-dose regim

62 In large trials, parenteral artesunate (an artemisinin derivative) reduce

63 perparasitemic African children treated with parenteral artesunate for severe malaria.

64 alaria were followed up after treatment with parenteral artesunate in Lambarene, Gabon, and Kumasi, G

65 Parenteral artesunate is recommended as first-line thera

66 However, parenteral BCG-prime-Apa-subunit-boost by a homologous r

67 ho can receive either orally administered or parenteral (bortezomib-based) therapy.

68 uently occur, and treating hypocalcemia with parenteral calcium administration remains the current pr

69 different routes of protein administration (parenteral, central intracerebroventricular and intrapar

70 Institute guideline-adherent (macrolide with parenteral cephalosporin) vs non-guideline-adherent anti

71 26,867 members exposed to 487,630 courses of parenteral cephalosporins over the 3-year study period.

72 ere we summarize the key differences between parenteral CMS/colistin and polymyxin B, and highlight t

73 , and standard combination therapy as use of parenteral colistin-carbapenem or colistin-tigecycline f

74 han or equal to 10% improvement in FEV1 with parenteral corticosteroid.

75 Are oral or parenteral corticosteroids associated with improved clin

76 symptoms between SA and NONSA persist after parenteral corticosteroids, suggesting a component of co

77 s a worsening asthma event requiring oral or parenteral corticosteroids.

78 Here we show that parenteral delivery of a single dose of recombinant FGF1

79 and liposomes to encapsulate such gasses for parenteral delivery.

80 A regimen of parenteral dextrose infusion that delays PH-induced hypo

81 unipolar or bipolar depression treated with parenteral doses of scopolamine.

82 formed in accordance with the pharmacopoeia, Parenteral Drug Association and International Organisati

83 tially protected against mortality following parenteral endotoxin administration.

84 Early combined parenteral/enteral nutrition delayed recovery irrespecti

85 all persons who have sustained a mucosal or parenteral exposure to HIV from a known infected source

86 axis (nPEP) is recommended after a sexual or parenteral exposure to human immunodeficiency virus (HIV

87 posures (95% CI, 1/1,428,571-1/96,154) and 8 parenteral exposures (95% CI, 1/200,000-1/35,971) (P = .

88 ering peptide therapeutics to women in a non-parenteral fashion as demonstrated by both blood levels

89 e pressure therapy, debridement, enteral and parenteral feeding, vitamin and mineral supplementation,

90 Parenteral fish-oil (FO) therapy is a safe and effective

91 sion and/or replacing the soybean oil with a parenteral fish-oil lipid emulsion or emulsions of mixed

92 or 48 hours, while receiving protocol-guided parenteral fluids and a norepinephrine infusion to maint

93 rd for in vitro drug dissolution studies for parenteral formulations.

94 Therefore, we hypothesized that parenteral glutamine supplementation may stimulate the i

95 +/- 2.2 days versus 16.7 +/- 2.3 days in the parenteral group (P = 0.007).

96 ) were included in the analysis (1191 in the parenteral group and 1197 in the enteral group).

97 30 days, 393 of 1188 patients (33.1%) in the parenteral group and 409 of 1195 patients (34.2%) in the

98 were no significant differences between the parenteral group and the enteral group in the mean numbe

99 ons were also significantly increased in the parenteral group at day 1 (p < 0.001) and day 5 (p = 0.0

100 glutamine concentrations were higher in the parenteral group than in the enteral group on postoperat

101 the enteral group had died (relative risk in parenteral group, 0.97; 95% confidence interval, 0.86 to

102 There were significant reductions in the parenteral group, as compared with the enteral group, in

103 was significantly higher in the enteral and parenteral groups than in the control group [median (IQR

104 d a boost dose with 90 mug of an inactivated parenteral H5N1 vaccine.

105 was highly protective in all regimens, three parenteral immunizations showed trends toward higher sur

106 ers at both systemic and mucosal sites after parenteral immunizations.

107 enzymes and the ability of oocysts to cause parenteral infections, the present study investigated th

108 t 1220pg/ml, i.e. levels typically following parenteral injections of leuprolide.

109 We aimed to evaluate the efficacy of the parenteral (intravenous or intramuscular) ondansetron vs

110 Administration of parenteral iron did not improve the phenotype.

111 a potential for harm from increasing use of parenteral iron in dialysis-dependent patients.

112 subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the tr

113 Long-Acting Parenterals (LAPs) have been used in the clinic to provi

114 ished data that evaluate these strategies in parenteral lipid management for the treatment and preven

115 ades, novel strategies for the management of parenteral lipids have improved morbidity and mortality

116 nthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products.

117 Use of a beta-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) se

118 bilirubin magnified the association between parenteral manganese and decreasing T1R.

119 ted the hypothesis that infants with greater parenteral manganese exposure have higher brain manganes

120 ed by MR imaging, than do infants with lower parenteral manganese exposure.

121 iation of relaxometry indexes with total and parenteral manganese exposures.

122 Infants exposed to parenteral manganese were enrolled in a prospective coho

123 controlled trial to evaluate the efficacy of parenteral methotrexate (25 mg/wk) in 111 patients with

124 Parenteral methotrexate is an effective treatment for pa

125 In a randomized controlled trial, parenteral methotrexate was not superior to placebo for

126 be considered when decisions for outpatient parenteral MSSA treatment are made.

127 Parenteral non-replicating rotavirus vaccines might offe

128 Moreover, parenteral NSAIDs were associated with much higher risk

129 ry drugs use during ARI episodes, especially parenteral NSAIDs, was associated with a further increas

130 ared with 18.5% in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% con

131 ntion) by nasojejunal tube (n = 61) or early parenteral nutrition (early parenteral nutrition, contro

132 e randomly assigned to EEN (n = 61) or early parenteral nutrition (EPN, n = 62) in addition to an ora

133 Home parenteral nutrition (HPN) and intestinal transplantatio

134 We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the

135 testinal failure (IF) and dependency on home parenteral nutrition (HPN).

136 The use of total parenteral nutrition (p = 0.03), longer duration of anti

137 rase and alkaline phosphatase than was early parenteral nutrition (P=0.001 and P=0.04, respectively),

138 echanical ventilatory support than was early parenteral nutrition (P=0.001), as well as a smaller pro

139 Compounding pharmacies often prepare parenteral nutrition (PN) and must adhere to rigorous st

140 Long-term parenteral nutrition (PN) carries the risk of progressiv

141 The impact of dilatation on parenteral nutrition (PN) dependence and survival has no

142 Standard trace element-supplemented neonatal parenteral nutrition (PN) has a high manganese content a

143 lant sterols, including stigmasterol, during parenteral nutrition (PN) have been linked with serum bi

144 Efforts to optimize early parenteral nutrition (PN) in extremely low-birth-weight

145 Parenteral nutrition (PN) increases risks of infections

146 The use of early parenteral nutrition (PN) is one potential strategy to a

147 Parenteral nutrition (PN) is the main treatment for inte

148 testinal failure (IF) treated with long-term parenteral nutrition (PN) may present with low bone mine

149 arly enteral nutrition (EN) may benefit from parenteral nutrition (PN) provided within 24 hours of IC

150 raphy or ultrasonography), laboratory tests, parenteral nutrition (PN), peripherally inserted central

151 ldren with intestinal failure (IF) depend on parenteral nutrition (PN).

152 ection for mesenteric infarction may require parenteral nutrition (PN).

153 with short bowel syndrome (SBS) who require parenteral nutrition (PN).

154 ical illness and are allegedly aggravated by parenteral nutrition (PN).

155 Enteral nutrient deprivation via total parenteral nutrition (TPN) administration leads to local

156 Total parenteral nutrition (TPN) is an invasive and advanced r

157 Total parenteral nutrition (TPN) is commonly used clinically t

158 l early enteral nutrition (NJEEN) with total parenteral nutrition (TPN), after pancreaticoduodenectom

159 We utilized a model of total parenteral nutrition (TPN), or enteral nutrient deprivat

160 el of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestinal muco

161 Mice that received total parenteral nutrition (TPN), which deprives the animals o

162 of gut failure (GF) with the need for total parenteral nutrition (TPN).

163 Early parenteral nutrition also increased the volume of adipos

164 Enteral or parenteral nutrition before, during, and after CABG may

165 tation of these amino acids with enteral and parenteral nutrition before, during, and after surgery m

166 tudy of a randomized controlled trial (Early Parenteral Nutrition Completing Enteral Nutrition in Adu

167 pecified analysis from this trial, the Early Parenteral Nutrition Completing Enteral Nutrition in Adu

168 with insulin did not lower glucagon, whereas parenteral nutrition containing amino acids increased gl

169 are important adjuncts to the elimination of parenteral nutrition dependence and need for intestinal

170 Early parenteral nutrition did not affect the time course of c

171 d that omega-3 fatty acid supplementation of parenteral nutrition does not improve mortality, infecti

172 In conclusion, early parenteral nutrition does not seem to impact AKI inciden

173 children to investigate whether withholding parenteral nutrition for 1 week (i.e., providing late pa

174 In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinicall

175 an or equal to 13, expected to require total parenteral nutrition for at least 5 days.

176 ntilated within 48 hours, received exclusive parenteral nutrition for more than or equal to 5 days, a

177 35%) of those who were alive at 28 days were parenteral nutrition free.

178 ndomized trials have found that supplemental parenteral nutrition has a deleterious effect in compari

179 Whether early versus late parenteral nutrition impacts the incidence and recovery

180 tinal absorption at the time of weaning from parenteral nutrition in a series of children after intes

181 ntration greater than 7 g/dl; (3) do not use parenteral nutrition in adequately nourished critically

182 trials have questioned the benefit of early parenteral nutrition in adults.

183 Use of early parenteral nutrition in critically ill patients in whom

184 GLP-2R signaling reduces the requirement for parenteral nutrition in human subjects with short-bowel

185 guidelines recommend the use of enteral over parenteral nutrition in patients undergoing gastrointest

186 gonlike peptide 2 that reduces dependence on parenteral nutrition in patients with short bowel syndro

187 Furthermore, early parenteral nutrition increased the amount of adipose tis

188 Parenteral nutrition is central to the care of very imma

189 The effect of early parenteral nutrition on clinical outcomes in critically

190 Patients received total parenteral nutrition prepared either with a lipid emulsi

191 Late parenteral nutrition prevented infections and accelerate

192 Early parenteral nutrition reduced the quality of the muscle t

193 omography severity index score at admission, parenteral nutrition requirement before or after radiolo

194 The use of parenteral nutrition should be limited within the first

195 rtage of injectable zinc available for total parenteral nutrition supplementation over the last 2 yea

196 ld promise as aids in restoring freedom from parenteral nutrition support; however, their long-term b

197 d a few days after the child had weaned from parenteral nutrition to exclusive enteral tube feeding.

198 judicious jejunostomy tube feeding, or total parenteral nutrition usage may reduce morbidity.

199 Is parenteral nutrition via peripherally inserted central c

200 Compared with short peripheral cannulas, parenteral nutrition via PICCs is associated with better

201 ent in protein and calories when appropriate parenteral nutrition was added to enteral sources.

202 Late parenteral nutrition was also associated with lower plas

203 Late parenteral nutrition was associated with a shorter durat

204 Early parenteral nutrition was given as control nutrition to o

205 tients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 hours after

206 atients receiving late parenteral nutrition, parenteral nutrition was not provided until the morning

207 se as survival, macronutrient absorption and parenteral nutrition weaning are improved after autologo

208 ety and efficacy of teduglutide as an aid to parenteral nutrition weaning.

209 -chain triglyceride, olive, and fish oils in parenteral nutrition were compared using an adjusted Cox

210 EPaNIC]), which compared early initiation of parenteral nutrition when enteral nutrition was insuffic

211 ur because of poor dietary intake, long-term parenteral nutrition without supplementation, and entera

212 l nutrition for 1 week (i.e., providing late parenteral nutrition) in the pediatric intensive care un

213 en enteral nutrition was insufficient (early parenteral nutrition) with tolerating a pronounced nutri

214 nutritional deficit for 1 week in ICU (late parenteral nutrition).

215 itive function, decreased functional status, parenteral nutrition, and pressure ulcers.

216 iglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins.

217 ection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% in the grou

218 s 6.5+/-0.4 days in the group receiving late parenteral nutrition, as compared with 9.2+/-0.8 days in

219 se receiving omega-3 fatty acid supplemented parenteral nutrition, but results were strongly influenc

220 n = 61) or early parenteral nutrition (early parenteral nutrition, control) by jugular vein catheter

221 tral line, and had 1 additional risk factor (parenteral nutrition, dialysis, surgery, pancreatitis, s

222 atic review assessed 37 trials that compared parenteral nutrition, enteral nutrition, or nutritional

223 For the 723 patients receiving early parenteral nutrition, parenteral nutrition was initiated

224 whereas for the 717 patients receiving late parenteral nutrition, parenteral nutrition was not provi

225 Use of alternative IV fat emulsions in parenteral nutrition, particularly olive and fish oil, w

226 When compared with lipid-free parenteral nutrition, patients who received fish oil had

227 ne therapy/apnea of prematurity, duration of parenteral nutrition, pulmonary hemorrhage, and white ma

228 and a need for opioid analgesic and enteral/parenteral nutrition, with an effect on patient survival

229 alue (hypocaloric) via enteral tube feeds or parenteral nutrition, with an equal protein allocation i

230 titis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and cysti

231 ns, phytosterols may promote liver injury in parenteral nutrition-associated liver disease.

232 once biochemical cholestasis is detected in parenteral nutrition-dependent patients is recommended.

233 sed for augmentation of energy absorption in parenteral nutrition-dependent subjects with short bowel

234 t multivisceral transplantation due to total parenteral nutrition-related liver disease.

235 U was clinically superior to providing early parenteral nutrition.

236 c dependence on central venous catheters for parenteral nutrition.

237 e a promising therapy to allow autonomy from parenteral nutrition.

238 to acquire intestinal failure requiring home parenteral nutrition.

239 d weight loss while receiving long term home parenteral nutrition.

240 y ill neonates, and patients receiving total parenteral nutrition.

241 enal replacement therapy observed with early parenteral nutrition.

242 t length of stay in comparison with standard parenteral nutrition.

243 U) is clinically superior to providing early parenteral nutrition.

244 9.2+/-0.8 days in the group receiving early parenteral nutrition; there was also a higher likelihood

245 scharge from the ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23;

246 d trials (RCTs) have investigated enteral or parenteral nutritional support, and evidence-based clini

247 Use of parenteral oestrogen could avoid the long-term complicat

248 vomiting, was compared in cases who received parenteral ondansetron and in cases who received traditi

249 Parenteral ondansetron is significantly more effective t

250 A total of 66 patients were included: 37 had parenteral ondansetron, 14 were treated with traditional

251 FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) t

252 f Ebola virus (EBOV) infection primarily use parenteral or aerosol routes of exposure.

253 provision of adjunctive nutritional support (parenteral or enteral nutrition, or nutritional suppleme

254 fic T-cell response peaked 32-52 weeks after parenteral or mucosal BCG-priming but waned significantl

255 patients who could be fed through either the parenteral or the enteral route to a delivery route, wit

256 ABG) were randomly assigned between enteral, parenteral, or no nutrition (control) from 2 d before, d

257 y 30 mug, then 60 mug if doses tolerated) to parenteral P2-VP8-P[8] subunit rotavirus or placebo inje

258 INTERPRETATION: The parenteral P2-VP8-P[8] vaccine was well tolerated and im

259 The mainstay of syphilis treatment is parenteral penicillin G despite the relatively modest cl

260 This may be due to parenteral phytosterols and/or the presence of pro-infla

261 f in vitro-in vivo correlations (IVIVCs) for parenteral polymeric microspheres has been very challeng

262 C for complex non-oral dosage forms (such as parenteral polymeric microspheres/implants, and transder

263 udes, preferences and acceptance of oral and parenteral PrEP among men who have sex with men (MSM) in

264 mbolus after TAVR and to investigate whether parenteral procedural anticoagulation strategies affect

265 in countries such as the United States where parenteral products of both colistin and polymyxin B are

266 ose who died of right heart failure received parenteral prostanoid therapy.

267 We hypothesized that delivery through the parenteral route is superior to that through the enteral

268 NP delivery is often via the parenteral route, reliant on administration using hypode

269 livery of VV vaccine in Hu-mice, but not the parenteral route, significantly reduces the humanlike lu

270 cine administered via respiratory mucosal or parenteral route.

271 didate vaccines are administered through the parenteral route.

272 Proteins administered through parenteral routes are often excluded from the brain beca

273 o exist to proteins administered through non-parenteral routes that bypass the BBB.

274 nd nutritional intake via oral, enteral, and parenteral routes to accurately assess the deficiency ri

275 erapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, pe

276 Both enteral and parenteral solutions were prepared with commercially ava

277 ent of PNALD include restricting the dose of parenteral soybean oil lipid emulsion and/or replacing t

278 the enteral group (1 patient) compared with parenteral supplementation (9 patients, P = 0.009).

279 th intestinal failure who are receiving home parenteral support (HPS), catheter-related bloodstream i

280 e, intestinal failure (IF) and dependence on parenteral support (PS) have been defined objectively as

281 However, the effects of teduglutide on parenteral support vary among patients.

282 tion with teduglutide treatment and baseline parenteral support volume (y = -0.3870x + 90.0279, r(2)

283 These findings may inform initial parenteral support volume adjustments and management of

284 ncrease urine production and reduce need for parenteral support volume in patients with short bowel s

285 We correlated parenteral support volume reduction with teduglutide tre

286 whom teduglutide has the largest effects on parenteral support volume response.

287 Changes in parenteral support volume were evaluated according to ba

288 The effects of teduglutide on absolute parenteral support volume were significantly greater in

289 on patients with SBS, we associated reduced parenteral support volume with baseline parenteral suppo

290 volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejun

291 uced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS featur

292 th short bowel syndrome who are dependent on parenteral support.

293 investigated this issue by using a model of parenteral TB immunization and intravascular immunostain

294 he value of local point-of-care diagnostics, parenteral therapies, and electrolyte replacement in EVD

295 n of infants, many of whom require long-term parenteral therapy and intestinal rehabilitation.

296 Parenteral transmission is a potential mode of acute HEV

297 ent local immune responses than conventional parenteral vaccination.

298 ccines against poliovirus and rotavirus, and parenteral vaccines against pertussis, tetanus, and meas

299 Mass vaccination campaigns with parenteral vaccines, and advances in oral vaccines for w

300 gs to treat infections, the most common were parenteral vancomycin (1103, 14.4%; 95% CI, 13.7%-15.2%)